Track Revive Therapeutics Ltd. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Revive Therapeutics Ltd. RVVTF · Stock Open Revive Therapeutics Ltd. in new tab

0.0150 USD
Add to portfolio
EPS
-0.02
P/B
-2.32
ROE
-1108.42
Beta
-1.85
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 27, 2026
EPS-0.02
Book Value-0.01
Price to Book-2.32
% Insiders1.512%

DCF Valuation

Tweak assumptions to recompute fair value for Revive Therapeutics Ltd. (RVVTF)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Revive Therapeutics Ltd. Logo Revive Therapeutics Ltd. Analysis (RVVTF)

Canada Health Care Official Website Stock

Is Revive Therapeutics Ltd. a good investment? Revive Therapeutics Ltd. (RVVTF) is currently trading at 0.0150 USD.

Earnings Schedule: Revive Therapeutics Ltd. is expected to release its next earnings report on May 27, 2026.

Investor FAQ

Does Revive Therapeutics Ltd. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Revive Therapeutics Ltd.?

Revive Therapeutics Ltd. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be May 27, 2026. The company currently has a trailing EPS of -0.02.

Company Profile

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develops Psilocybin, which is in Phase 1 clinical study for treating methamphetamine use disorder; and Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases. Revive Therapeutics Ltd. is based in Toronto, Canada.

Exchange Ticker
PNK (United States) RVVTF
CNQ (Canada) RVV.CN
FRA (Germany) 31R.F
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
May 20, 2016 1.27
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion